Transient Ischemic Attack News and Research

RSS
A transient ischemic attack (TIA) is a transient stroke that lasts only a few minutes. It occurs when the blood supply to part of the brain is briefly interrupted. TIA symptoms, which usually occur suddenly, are similar to those of stroke but do not last as long. Most symptoms of a TIA disappear within an hour, although they may persist for up to 24 hours. Symptoms can include: numbness or weakness in the face, arm, or leg, especially on one side of the body; confusion or difficulty in talking or understanding speech; trouble seeing in one or both eyes; and difficulty with walking, dizziness, or loss of balance and coordination.
Researchers examine effects of lowering blood pressure after onset of ischemic stroke

Researchers examine effects of lowering blood pressure after onset of ischemic stroke

‘Pioneering’ non-invasive coronary plaque imaging revealed

‘Pioneering’ non-invasive coronary plaque imaging revealed

Research findings leave considerable room for improvement in stroke treatment

Research findings leave considerable room for improvement in stroke treatment

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Study evaluates implementation of out-of hospital stroke policy in some Chicago hospitals

Study evaluates implementation of out-of hospital stroke policy in some Chicago hospitals

Research: Stroke patients may be more likely to develop problems with memory and thinking

Research: Stroke patients may be more likely to develop problems with memory and thinking

Study: One in four stroke survivors suffer from symptoms of PTSD

Study: One in four stroke survivors suffer from symptoms of PTSD

Smartphone solutions for clinical trials

Smartphone solutions for clinical trials

Implantation of new mechanical heart valve reduces anticoagulation therapy in AVR patients

Implantation of new mechanical heart valve reduces anticoagulation therapy in AVR patients

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

Undetected arrhythmia could underlie some wake-up strokes

Undetected arrhythmia could underlie some wake-up strokes

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Dabigatran decreases risk of recurrent venous thromboembolism

Dabigatran decreases risk of recurrent venous thromboembolism

Study assesses ischaemic and haemorrhagic risk linked with history of stroke or TIA

Study assesses ischaemic and haemorrhagic risk linked with history of stroke or TIA

Positive data from POZEN's PA32540 Phase 3 studies presented at AHA 2013 stroke conference

Positive data from POZEN's PA32540 Phase 3 studies presented at AHA 2013 stroke conference

Marijuana may double stroke risk in young adults

Marijuana may double stroke risk in young adults

New evidence supports thrombolysis in presence of contraindications

New evidence supports thrombolysis in presence of contraindications

Low-income groups slow to seek treatment for stroke

Low-income groups slow to seek treatment for stroke

Stroke patients with PTSD less likely to adhere to treatment regimens

Stroke patients with PTSD less likely to adhere to treatment regimens

Updated U.S. prescribing information for Boehringer Ingelheim’s Pradaxa

Updated U.S. prescribing information for Boehringer Ingelheim’s Pradaxa